| Document |
Document Title |
|
WO/2020/115556A1 |
Combination therapies comprising administering radioimmunoconjugates and one or more checkpoint inhibitors.
|
|
WO/2020/115548A1 |
Combination therapies comprising administering radioimmunoconjugates and DNA damage response inhibitors.
|
|
WO/2020/114353A1 |
A replaceable module (200) for a radioisotope operating system (10) and a radioisotope operating system (10). The replaceable module (200) for the radioisotope operating system (10) comprises: a base (210); a holding portion (211) provid...
|
|
WO/2020/108720A1 |
The present invention relates to novel tetrazine compounds of formula I, wherein one of R1-R5 is 18F, for use in pretargeted in vivo imaging. The compounds are suitable for use in click chemistry, i.e. reactions that join a targeting mol...
|
|
WO/2020/108688A1 |
The Invention relates to a compound of general formula (I), where Ar is a pyridine ring. Also provided is a precursor compound for preparing a compound of formula (I), which has a nucleofuge in place of a group R1.
|
|
WO/2020/113047A1 |
This invention provides a compositions of matter comprising a therapeutic protein population (such as a HuM195 antibody population) wherein (a) each therapeutic protein in the population is conjugated to one or more actinium atoms, (b) e...
|
|
WO/2020/107078A1 |
Provided herein is a dendrimer comprising: i) a core unit (C); and ii) building units (BU), wherein the core unit is covalently attached to at least two building units; the dendrimer having from two to six generations of building units; ...
|
|
WO/2020/113130A1 |
A therapeutic agent has an antineoplastic drug bonded with an X-ray-cleavable bond to cobalt of cobalamin. In embodiments, the drug is doxorubicin, paclitaxel, methotrexate, erlotinib, chlorambucil, dasatinib, SN38, colchicine, or gefiti...
|
|
WO/2020/113091A1 |
Systems and devices for applying radiation to a target area, for example for maintaining functioning drainage blebs or functioning drainage holes in the eye, e.g., to reduce intraocular pressure (IOP) of an eye being treated for glaucoma...
|
|
WO/2020/109523A1 |
The present invention provides compounds according to General Formula (1 )(i) or (1 )(ii): wherein A is a diagnostic or therapeutic agent comprising a binding site for a tumor antigen, and the spacer comprises at least one C-N bond.
|
|
WO/2020/108753A1 |
The present invention provides novel compounds comprising an ibuprofene moiety that are useful as radiopharmaceuticals, imaging agents and for treatment of cancer.
|
|
WO/2020/103392A1 |
Disclosed in the present invention are an 18F-PET/CT tracer comprising 7-deazaadenine base as a parent nucleus and a preparation method therefor. Disclosed in the present invention are a compound represented by formula I or a pharmaceuti...
|
|
WO/2020/104627A1 |
The invention relates to a method for labeling a target compound with a radiometal by photochemically induced conjugation. Furthermore, a chelating compound for use in said method is provided. The chelating compound is characterized by a...
|
|
WO/2020/099398A1 |
A chelating compound of formula (I) or a pharmaceutically acceptable salt thereof and its complexes with metals or radioisotopes thereof. The invention further relates to the preparation of such ligand and complexes as well as to their u...
|
|
WO/2020/102324A2 |
Described herein are compositions for liquidly injectable, self-stabilizing biopolymers for the delivery of radionuclide brachytherapy. Also described herein are methods of using the compositions.
|
|
WO/2020/102348A1 |
Provided herein are compositions and methods for preparing albumin-targeting moieties that feature a thioamide linkage. Methods to use the albumin targeting molecules to generate drugs with improved in vivo pharmacodynamics and biodistri...
|
|
WO/2020/099537A1 |
The present invention is directed to benzazepin-1,7-diol-derived compounds (I) for use in the diagnosis of NMDA (N-methyl-D-aspartate) receptor-associated diseases or disorders by positron emission tomography (PET), single-photon emissio...
|
|
WO/2020/099770A1 |
The invention relates to a method for transferring a radioisotope that is attached to a first stationary phase contained in a first chromatography column to a second stationary phase contained in a second chromatography column, in order ...
|
|
WO/2020/099769A1 |
The invention relates to a method for preparing one or more generators with a high radium-228 content from an aqueous solution comprising thorium-232 and radium-228. The generator(s) can be used, in particular, for producing thorium-228,...
|
|
WO/2020/094899A1 |
The invention relates to azamacrocyclic ligands which have non-adjacent nitogen atoms connected to ethylene chains and which are reinforced with an ethylene/propylene bridge which crosses the structure, and which contain amide groups wit...
|
|
WO/2020/095927A1 |
The present invention relates to a method comprising diluting aqueous solution A, which contains particles Z comprising self-organizing molecules as a particle-constituting ingredient and which contains a water-miscible organic solvent i...
|
|
WO/2020/089379A1 |
The present disclosure relates to the synthesis of radionuclide complex solutions, in particular for their use in the commercial production of radioactive drug substances, for diagnostic and/or therapeutic purposes. In particular, the sy...
|
|
WO/2020/089819A1 |
A method of treating a patient with a tumor, and kits (200) for such treatment. The method includes administering, to the patient, a substance (204) which activates cytoplasmatic sensors for intracellular pathogen in the tumor and treati...
|
|
WO/2020/087794A1 |
The present application discloses an F-18 labeled 5-aminolevulinic acid derivative, a synthesis method therefor, and an application thereof. A radioactive probe provided in an implementation of the present application has a long radioact...
|
|
WO/2020/088767A1 |
The present disclosure relates to the synthesis of radionuclide complex solutions, in particular for their use in the commercial production of radioactive drug substances, for diagnostic and/or therapeutic purposes. In particular, the sy...
|
|
WO/2020/092602A1 |
Disclosed herein is a pH activated nanoparticle that can be used to deliver labile therapeutic or diagnostic agents to the cytoplasm of cells. These nanoparticles allow the agents to escape the endosome by releasing a gas in an amount ef...
|
|
WO/2020/084623A2 |
A fusogenic liposome comprising a detectable agent and optionally a cytotoxic drug in its internal aqueous compartment or bound to the liposome membrane is provided, wherein said fusogenic liposome comprises a lipid bilayer comprising a ...
|
|
WO/2020/085238A1 |
In order to improve the stability of a precursor compound of a radioactive fluorine-labeled compound, the present invention provides a stabilized composition which contains, as a main component, a salt of a compound represented by formul...
|
|
WO/2020/085883A1 |
The present invention relates to a sensing technique for determining, from outside a living body, the location of a medical device inserted into the living body, and more particularly, to a system for determining a location inside a livi...
|
|
WO/2020/084267A1 |
The present invention concerns compounds of the following general structure (I): (I) in which A, B, C, D, L1, L2, L3, L4, n and m are as defined in claim 1. The invention also concerns the use of these compounds for an application for ne...
|
|
WO/2020/083853A1 |
The invention relates to a marking precursor comprising a chelator or fluorination group for radiolabelling with 44Sc, 47Sc, 55Co, 62Cu, 64Cu, 67Cu, 66Ga, 67Ga, 68Ga, 89Zr, 86Y, 90Y, 90Nb, 99mTc, 111ln, 135Sm, 140Pr, 159Gd, 149Tb, 160Tb,...
|
|
WO/2020/085882A1 |
The present invention relates to a detection technology for ex vivo confirmation of the location of a medical device inserted into the body and, more particularly, to a balloon inflation composition and system, for in vivo location confi...
|
|
WO/2020/081988A1 |
The presently disclosed subject matter provides for methods and compositions for treating cancer (e.g., pancratic cancer). It relates to antigen recognizing receptor (e.g., chimeric antigen receptors (CARs)) that specifically target Sial...
|
|
WO/2020/081174A1 |
Compositions, methods, and uses of an alpha emitter are provided in which the alpha emitter is coupled to carrier protein via a cleavable coupling moiety. The coupling moiety is preferably cleavable in an acidic tumor microenvironment, a...
|
|
WO/2020/080842A1 |
The present invention pertains to: a compound which binds to a prostate-specific membrane antigen (PSMA) and inhibits the activity thereof; and a pharmaceutical composition for diagnosing or treating prostate cancer, the pharmaceutical c...
|
|
WO/2020/081522A1 |
Excessive deposition of extracellular matrix is a hallmark of Idiopathic pulmonary fibrosis (IPF), it is advantageous to target the cells and the mechanisms associated with this process. By targeting myofibroblasts (specialized contracti...
|
|
WO/2020/081410A2 |
The present invention relates to radiolabeled LPA1 receptor antagonists of Formula (I) or pharmaceutically acceptable salts thereof, wherein all the variables are as defined herein, which are useful for the quantitative imaging of LPA1 r...
|
|
WO/2020/080593A1 |
The present invention relates to: a near-infrared imaging probe compound for targeting hepsin which is overexpressed in metastatic cancer; and a composition for near-infrared imaging for metastatic cancer diagnosis, and a pharmaceutical ...
|
|
WO/2020/076954A1 |
The disclosure teaches antibodies that are useful, inter alia, in methods for detecting and treating human cancer. In a particular aspect, the disclosure teaches novel antibodies that are useful for detecting and treating human breast ca...
|
|
WO/2020/077259A1 |
Provided herein are compositions and related methods for treating and/or identifying patients likely to respond to treatments for prostate cancer.
|
|
WO/2020/075746A1 |
Provided is a stable pharmaceutical composition or the like containing a tagged site-antihuman antibody Fab fragment complex. This pharmaceutical composition containing a tagged site-antihuman antibody Fab fragment complex has a pH adjus...
|
|
WO/2020/074691A1 |
The present disclosure relates to gastrin-releasing peptide receptor (GRPR) targeting radiopharmaceuticals and uses thereof. In particular, the present disclosure relates to a pharmaceutical composition comprising radiolabeled GRPR-antag...
|
|
WO/2020/077270A1 |
Provided herein are methods for assessing a subject with prostate cancer. The methods are also directed to or may further comprise treating the subject and/or making treatment management decisions based on the assessing.
|
|
WO/2020/068653A1 |
The disclosure provides compositions comprising multi-specific compounds, including a compound that targets a phosphatase and a receptor tyrosine kinase agonist. Also provided are methods for the treatment of conditions associated with a...
|
|
WO/2020/065045A1 |
The present invention relates to a compound of formula (1) (I), wherein Y3 is O or S, wherein s, t, u and w are 0 or 1, wherein i is an integer of from 1 to 3, wherein j is an integer of from 3 to 5, and wherein Z1, Z2 and Z3 are selecte...
|
|
WO/2020/069433A1 |
Antigen binding constructs that bind to CD8, as well as formulations and methods of using them, are described herein.
|
|
WO/2020/064693A1 |
The present invention relates to combination therapies of radiolabelled somatostatin receptor binding compounds with PARR inhibitors.
|
|
WO/2020/059986A1 |
The present invention relates to a method for preparing a fluorine-18-labeled fluoromethyl-substituted radiopharmaceutical using selective azide substitution reaction, the method comprising: a first step for obtaining [18F]fluoride from ...
|
|
WO/2020/061458A1 |
The disclosure pertains to drug delivery conjugates for targeted therapy. The disclosure relates to methods of treating PSMA expressing cancers with a combination of compounds of the formulas I-Lu or Ia-Lu, and I-Ac or Ia-Ac. The disclos...
|
|
WO/2020/055175A1 |
The present invention relates to a composition for detecting hydrogen sulfide or measuring a concentration of hydrogen sulfide, and a composition comprising same as an effective ingredient for diagnosing or imaging in vivo inflammation, ...
|
